Recently, the National Medical Insurance Bureau has uniformly deployed various provinces to carry out standardized governance of medical service prices, promote reasonable price reductions for some large-volume and high-priced inspection and testing items, further reduce the burden on patients to see doctors, and promote the relative balance of inspection and testing prices among provinces. Which items will be focused on? At present, there are more than 2,000 inspection and testing items in various provinces across the country. Affected by factors such as information barriers, the prices of some items vary greatly in different provinces. For example, the thromboelastogram test, which is a test used to evaluate coagulation function, costs 360 yuan per time in some places and only 100 yuan per time in some places, which is several times different. The reason behind this is mainly that the procurement costs of some inspection reagents or equipment are inflated, resulting in ...
Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
Recently, Wellizbo announced that its independently developed and globally intellectual property-owned Class 1 new drug LBL-034 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell engaging antibodies targeting GPRC5D and CD3 developed using Wellizbo’s independently developed and intellectual property-owned CD3 bispecific antibody technology platform “LeadsBodyTM”. It is the third CD3 T cell connector targeting GPRC5D to enter the clinical stage in the world. Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for about 10% of hematological malignancies and about 1% of all tumor diseases. MM is still an incurable malignancy. With multiple lines of medication, the interval between relapses will become shorter and shorter, and eventually evolve into RRMM, which seriously threatens the life and health of patients. ...
Recently, the National Medical Insurance Administration has attracted attention through the verification of drug traceability codes. What is a drug traceability code? What does it mean if a drug traceability code is scanned repeatedly? What role does the drug traceability code play in ensuring the security of medical insurance funds? How to use drug traceability codes? What is a drug traceability code? Answer: The drug traceability code is the “electronic ID card” of the drug. It is usually composed of a series of numbers, letters and (or) symbols. It is marked in a prominent position on the drug packaging box. It is the unique identity label given to each box of drugs from the time of production. If the drug traceability code appears repeatedly during the circulation process, the drug may be a “returned drug”, a counterfeit drug, or sold in a scrambled manner. The drug traceability code has three ...
On October 31, CSPC Pharmaceutical Group issued a third-quarter profit warning announcement. It is expected that the company’s net profit in the first three quarters of this year will decrease by about 16% year-on-year from 4.495 billion yuan in the same period last year. In total, CSPC Pharmaceutical Group’s net profit in the first three quarters of this year is about 3.776 billion yuan. According to the interim report, CSPC Pharmaceutical Group’s revenue in the first half of the year was 16.284 billion yuan, a year-on-year increase of 1.27%, and its net profit was 3.02 billion, a year-on-year increase of 1.8%. According to this calculation, the net profit in the third quarter was only 760 million yuan, while the same period last year, this figure was 1.528 billion yuan. In other words, the net profit in the third quarter of this year was halved, a year-on-year decrease of 50%. As ...
Recently, Asia Pacific Pharmaceuticals issued the “Announcement on the Progress of Liquidation and Cancellation of Joint Ventures”. A Biotech company that it established with an investment of approximately RMB 35.84 million in 2019 has completed the deregistration procedures. Asia Pacific Pharmaceuticals is mainly engaged in pharmaceutical manufacturing and CRO service businesses, covering chemical pharmaceutical preparations, chemical APIs, and pharmaceutical research and development. Its main products include roxithromycin capsules, cephalexin capsules, azithromycin dispersible tablets, and azithromycin for injection. The Biotech business area that was deregistered and liquidated this time was the new track that Asia Pacific Pharmaceuticals first contacted at the time – industrial hemp. It is reported that according to the different mass concentrations of tetrahydrocannabinol (THC) contained in hemp, hemp can be divided into industrial hemp, intermediate hemp, and recreational hemp. Industrial hemp refers to hemp with a THC content of less than 0.3%, which does not show psychoactive ...
Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. On the morning of November 6th, at the 7th China International Import Expo (CIIE), Jean Christophe Pointeau, President of Pfizer China, a multinational pharmaceutical giant, revealed that the company will launch the “Pfizer China 2030 Strategy” during this year’s CIIE. From 2025 to 2030, Pfizer will invest 1 billion US dollars, about 7.5 billion yuan, in China. Pfizer will continue to invest in accelerating innovation, improving diagnostic capabilities and treatment standards, and promoting the development of the local biotechnology industry to support the ‘Healthy China 2030’ initiative. This strategy is based on three pillars: firstly, accelerating the launch of ...
Introduction: Has the best potential in its class Recently, Weili Zhibo announced that its independently developed Class 1 new drug LBL-034, which has global intellectual property rights, has been granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell linker antibody targeting GPRC5D and CD3, developed using LeadsBody TM, a CD3 bispecific technology platform independently developed by Weili Libo with intellectual property rights. It is the third CD3 T cell linker targeting GPRC5D to enter the clinical stage worldwide. Figure 1: GPRC5D/CD3 dual antibody under global research Image source: Pharmaceutical Intelligence Data Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for approximately 10% of hematological malignancies and 1% of all tumor diseases. MM is still an incurable malignant tumor. With ...
After optimizing the overall structure of Ziqiang Sheng, personnel change messages often occur. Recently, Larry Jones, Global Vice President of Medical Technology and Group Chief Information Officer at Johnson&Johnson, announced his decision to resign. He will retire from Johnson&Johnson Medical Devices, and details such as when he will officially resign or who will take over are still unknown. 35 year veteran resigns, Johnson&Johnson personnel changes frequently Larry Jones is an experienced veteran at Johnson&Johnson Medical, having served for 35 years. During his tenure at Johnson&Johnson’s Medical Devices division, Larry Jones was particularly dedicated to driving innovation in the fields of oncology, orthopedics, cardiovascular and general surgery, and revolutionizing digital surgical connectivity solutions through advanced technologies such as surgical robots and machine learning platforms. Larry Jones has served as the trans regional global CIO of Janssen Pharmaceuticals for more than six years. He is the executive member of the Johnson African ...
On November 7, 2024, Shanghai, China – Today, Vantiv, a kidney care company that Baite Medical plans to spin off, held a launch ceremony for its new generation continuous blood purification equipment PrisMax at the 7th China International Import Expo. Mr. Wang Xiaoyu, Vice President of Emergency and Critical Care Business in China, and Ms. Liu Ying, Senior Director of Regulatory Affairs and Quality Department in Asia Pacific and China, delivered speeches on behalf of Baite Medical, which plans to spin off its kidney care company. They unveiled the company’s leadership team and strategic partners on site, and explained the insights of this locally implemented initiative in upgrading diagnosis and treatment services, responding to national policies, and enhancing clinical value. As one of the advocates and industry leaders of the global concept of continuous blood purification, Vantiv has advanced emergency and critical care therapies that can support both kidney and ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.